– Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-.
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need
–Multiple vepdegestrant studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib. | May 5, 2023